Epigenomic ctDNA Assay Predicts Recurrence in Resected Melanoma
An epigenomic ctDNA assay reading methylation signatures predicts recurrence in resected melanoma, potentially guiding adjuvant therapy and follow-up decisions.
Section
Skin Cancer & Surgery
Melanoma and keratinocyte carcinoma, screening, Mohs and surgical outcomes.
Florida's Melanoma Burden Concentrated in Older Adults, FAU Reports
Florida Atlantic University finds melanoma cases and deaths in Florida peak among older adults, highlighting late-detection risk…
DNA Methylation Rewrites Melanoma as It Spreads, Study Finds
Melanoma changes its methylation program as it metastasizes, making spread tumors molecularly distinct from the primary lesion —…
Attention-Guided Fair AI Modeling for Skin Cancer Diagnosis Published in Nature
A Nature publication introduces attention-guided fair artificial intelligence modeling for skin cancer diagnosis, aiming to reduc…
Dunedin Dermatology Access Under Fire After Rare Cancer Goes Undiagnosed
A rare, 'debilitating' cancer went undiagnosed in Dunedin, RNZ reports, prompting public calls for better dermatology services in…
MAPK Signaling in Melanoma: From BRAF and NRAS to Combination Therapy
A Frontiers review maps BRAF- and NRAS-driven MAPK signaling in malignant melanoma and lays out the logic behind precision combin…
Liquid Nitrogen Handling in Mohs Labs: Beyond Convenience
A JAAD commentary published online October 10, 2026, by Ji-Long Shi urges Mohs laboratories to optimize liquid nitrogen handling…
JAAD Expert Opinion Weighs Hedgehog Inhibitors in the Immunotherapy Era for Advanced BCC
JAAD published an expert opinion on October 8, 2026 comparing efficacy and tolerability of hedgehog pathway inhibitors for locall…
Skin Cancer Burden Projected to Surge Through 2050
Skin cancer incidence is projected to climb through 2050, with low- and middle-income regions facing the steepest rise, straining…
Vanderbilt Patient With Melanoma Receives TIL Therapy
Vanderbilt Health News has issued a one-line notice confirming a melanoma patient received tumor-infiltrating lymphocyte therapy,…